Clinical trial
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
NCT01710709 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- December 31, 2016
- Enrollment
- 748 (actual)
- Sites
- 142
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar i